Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Insulin-like growth factor (IGF) signaling is implicated in human cancer cell growth and survival.
• IGF1 receptor (IGF1R) inhibitors demonstrate antineoplastic activity in preclinical models and early clinical trials.

Purpose of the Study:

• To review the role of IGF1 signaling in cancer.
• To discuss IGF1R-targeted therapies, clinical trial outcomes, and the search for predictive biomarkers.

Main Methods:

• Review of existing literature on IGF1 signaling in neoplasia.
• Analysis of preclinical and clinical trial data for IGF1R inhibitors.
• Exploration of microarray data for IGF1-related expression signatures.

Main Results:

• IGF1R inhibitors show promise but benefit only a subset of patients, with observed toxicities.
• Microarray analyses reveal IGF1 expression signatures correlating with poor breast cancer prognosis and treatment response.
• Identifying predictive biomarkers is essential for patient stratification.

Conclusions:

• Further characterization of IGF1 signaling pathways is needed to identify predictive biomarkers and novel therapeutic targets.
• Personalized approaches are required to optimize anti-IGF1R therapy efficacy and minimize toxicity.